These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 12099972)

  • 1. PPARgamma and the thiazolidinediones: molecular basis for a treatment of 'Syndrome X'?
    Sewter C; Vidal-Puig A
    Diabetes Obes Metab; 2002 Jul; 4(4):239-48. PubMed ID: 12099972
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists.
    Olefsky JM
    J Clin Invest; 2000 Aug; 106(4):467-72. PubMed ID: 10953021
    [No Abstract]   [Full Text] [Related]  

  • 3. Biology and toxicology of PPARgamma ligands.
    Tugwood JD; Montague CT
    Hum Exp Toxicol; 2002 Aug; 21(8):429-37. PubMed ID: 12412636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin resistance, diabetes, and atherosclerosis: thiazolidinediones as therapeutic interventions.
    Raji A; Plutzky J
    Curr Cardiol Rep; 2002 Nov; 4(6):514-21. PubMed ID: 12379175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [PPARgamma and insulin resistance].
    Girard J
    Ann Endocrinol (Paris); 2002 Apr; 63(2 Pt 2):1S19-22. PubMed ID: 12037503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pioglitazone].
    Kobayashi M; Iwata M; Hiratani K
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():429-37. PubMed ID: 12387029
    [No Abstract]   [Full Text] [Related]  

  • 7. [PPARgamma and thiazolidinediones, something more than a treatment for diabetes].
    Medina G; Sewter C; Puig AJ
    Med Clin (Barc); 2000 Sep; 115(10):392-7. PubMed ID: 11262358
    [No Abstract]   [Full Text] [Related]  

  • 8. [Antidiabetic effect of thiazolidinediones].
    Girard J
    Journ Annu Diabetol Hotel Dieu; 2001; ():33-45. PubMed ID: 11565467
    [No Abstract]   [Full Text] [Related]  

  • 9. [Physiological function of peroxisome proliferator-activated receptor].
    Yanase T
    Fukuoka Igaku Zasshi; 1999 Dec; 90(12):443-7. PubMed ID: 10655664
    [No Abstract]   [Full Text] [Related]  

  • 10. [Mechanisms of thiazolidinedione derivatives for hypoglycemic and insulin sensitizing effects].
    Sugiyama Y
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():416-21. PubMed ID: 12387027
    [No Abstract]   [Full Text] [Related]  

  • 11. [Rosiglitazone (BRL-49653)].
    Oka Y
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():438-41. PubMed ID: 12387030
    [No Abstract]   [Full Text] [Related]  

  • 12. A gut check for PPARgamma.
    Wu GD; Lazar MA
    Gastroenterology; 1998 Nov; 115(5):1283-5. PubMed ID: 9797386
    [No Abstract]   [Full Text] [Related]  

  • 13. [New antidiabetic in "virtual reality". Eye to eye with insulin resistance].
    MMW Fortschr Med; 2000 May; 142(19):52. PubMed ID: 10850084
    [No Abstract]   [Full Text] [Related]  

  • 14. Peroxisome proliferator-activated receptor gamma (PPargamma) as a novel target for prostate cancer.
    Smith MR; Kantoff PW
    Invest New Drugs; 2002 May; 20(2):195-200. PubMed ID: 12099579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes.
    Matsusue K; Haluzik M; Lambert G; Yim SH; Gavrilova O; Ward JM; Brewer B; Reitman ML; Gonzalez FJ
    J Clin Invest; 2003 Mar; 111(5):737-47. PubMed ID: 12618528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension.
    Barroso I; Gurnell M; Crowley VE; Agostini M; Schwabe JW; Soos MA; Maslen GL; Williams TD; Lewis H; Schafer AJ; Chatterjee VK; O'Rahilly S
    Nature; 1999 Dec 23-30; 402(6764):880-3. PubMed ID: 10622252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones.
    Norris AW; Chen L; Fisher SJ; Szanto I; Ristow M; Jozsi AC; Hirshman MF; Rosen ED; Goodyear LJ; Gonzalez FJ; Spiegelman BM; Kahn CR
    J Clin Invest; 2003 Aug; 112(4):608-18. PubMed ID: 12925701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Thiazolidinediones in type 2 diabetes. Role of peroxisome proliferator-activated receptor gamma (PPARgamma)].
    Dubois M; Vantyghem MC; Schoonjans K; Pattou F
    Ann Endocrinol (Paris); 2002 Dec; 63(6 Pt 1):511-23. PubMed ID: 12527853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Involvement of PPARgamma in the pathogenesis of hypertension and hypertensive target-organ damage].
    Itoh H
    Nihon Rinsho; 2004 Mar; 62 Suppl 3():179-90. PubMed ID: 15171366
    [No Abstract]   [Full Text] [Related]  

  • 20. Thiazolidinediones in the treatment of insulin resistance and type II diabetes.
    Saltiel AR; Olefsky JM
    Diabetes; 1996 Dec; 45(12):1661-9. PubMed ID: 8922349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.